DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
8.33
-0.46 (-5.23%)
At close: Nov 16, 2026, 4:00 PM EST
8.35
+0.02 (0.24%)
After-hours: Nov 16, 2026, 7:30 PM EST
DiaMedica Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
35
Market Cap
449.47M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MiMedx Group | 303.73M |
| Phathom Pharmaceuticals | 274.88M |
| Gyre Therapeutics | 110.06M |
| Ovid Therapeutics | 1.45M |
| Oculis Holding AG | 1.12M |
| Shattuck Labs | 1.00M |
| Neurogene | 925.00K |
DMAC News
- 3 days ago - DiaMedica Therapeutics Earnings Call Transcript: Q3 2026 - Transcripts
- 3 days ago - DiaMedica Therapeutics Earnings release: Q3 2026 - Filings
- 3 days ago - DiaMedica Therapeutics Quarterly report: Q3 2026 - Filings
- 4 days ago - DiaMedica Therapeutics reports Q3 EPS (21c), consensus (21c) - TheFly
- 4 days ago - DiaMedica Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights - Business Wire
- 11 days ago - DiaMedica Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Business Update November 13, 2026 - Business Wire
- 25 days ago - DiaMedica announces enrollment of 200th patient in ReMEDy2 Phase 2/3 trial - TheFly
- 25 days ago - DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial - Business Wire